SIWA318H
Pancreatic Ductal Adenocarcinoma (PDAC)
PreclinicalActive
Key Facts
Indication
Pancreatic Ductal Adenocarcinoma (PDAC)
Phase
Preclinical
Status
Active
Company
About SIWA Therapeutics
SIWA Therapeutics is an early-stage biotech focused on the emerging field of senolytics—therapies that clear senescent or 'zombie' cells. The company's platform centers on antibodies designed to target advanced glycation end products (AGEs), which are biomarkers on senescent cells, offering a potential new approach for treating age-related conditions like pancreatic cancer. A recent preclinical study published in Scientific Reports, in collaboration with TGen/City of Hope, demonstrated that its lead candidate, SIWA318H, could slow pancreatic tumor growth by reshaping the tumor microenvironment. The company is privately held and currently in the preclinical development phase.
View full company profileTherapeutic Areas
Other Pancreatic Ductal Adenocarcinoma (PDAC) Drugs
| Drug | Company | Phase |
|---|---|---|
| M2T™ Program (unspecified) | Leukogene Therapeutics | Preclinical |
| IPB-106 | Interplay Bio | Discovery |
| IPB-107 | Interplay Bio | Discovery |
| PurIST® | GeneCentric Therapeutics | Commercial |